SD HB1016

Amends South Dakota's controlled substances definitions to add "chemically derived cannabinoid" as a defined term, excluding cannabinoids produced by natural decarboxylation, non-psychoactive cannabinoids, and topical cream products

Adds multiple synthetic opioids to Schedule I, including nitazene-class compounds (isotonitazene, butonitazene, metonitazene, protonitazene, and others) and substances like ethylphenidate and amineptine

Expands Schedule I to include additional opioid derivatives such as Zipeprol, 2-Methyl AP-237, and Brorphine

Declares an emergency, making the act effective immediately upon passage and approval rather than following the standard effective date